CytomX Therapeutics Inc
CytomX Therapeutics Inc (CTMX) Covered Calls
CytomX Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 67.86%, average versus the past year. CTMX's highest covered call setup is the $3.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 47.06% out of the money with 63 days to expiration, a 54.41% return until expiration, and a 315.24% theoretical annualized return. Across the setups shown, annualized returns run from 60.19% to 315.24% at strikes between $3.00 and $7.00, with 63 to 434 days to expiration, as of Nov 13, 2026.
Read more
Running CTMX covered calls helps you generate income from CytomX Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CTMX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CTMX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CTMX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CTMX covered call is worth writing.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.
| 2027-01-15 | 63 | 3.00 | 47.06 | 0.15 | 0.35 | 111.00 | 54.41 | 315.24 | -7.35 | +0.38 | 537 | 0.20 |
| 2028-01-21 | 434 | 7.00 | 243.14 | 0.25 | 0.90 | 521.00 | 255.39 | 214.79 | -12.25 | +0.48 | 212 | 0.65 |
| 2027-05-21 | 189 | 4.00 | 96.08 | 0.30 | 0.90 | 226.00 | 110.78 | 213.95 | -14.71 | +0.54 | 70 | 0.60 |
| 2028-01-21 | 434 | 5.00 | 145.10 | 0.05 | 0.80 | 301.00 | 147.55 | 124.09 | -2.45 | +0.43 | 1,753 | 0.75 |
| 2027-05-21 | 189 | 3.00 | 47.06 | 0.05 | 1.05 | 101.00 | 49.51 | 95.61 | -2.45 | +0.55 | 55 | 1.00 |
| 2028-01-21 | 434 | 4.00 | 96.08 | 0.20 | 0.75 | 216.00 | 105.88 | 89.05 | -9.80 | +0.48 | 593 | 0.55 |
| 2028-01-21 | 434 | 3.00 | 47.06 | 0.50 | 0.80 | 146.00 | 71.57 | 60.19 | -24.51 | +0.59 | 266 | 0.30 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank67.86% Moderate
- Market cap (M$)443
- 52 weeks high-75.27%
- 52 weeks low8.56%
- Analyst recommendationStrong Buy
1.12 - Target price$12.38
509.85% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-0.46
- EPS growth next 5 years—
As of Nov 20, 2026